Follow-up data for patients with detection of a regulatory domain mutation. (A) Available quantitative RT-PCR data for BCR-ABL in patients with a SH3-SH2 domain mutation were graphed for the period of 12 months before to 36 months after the index sample with mutation detection. (B) Clinical timelines corresponding to the quantitative RT-PCR data are shown to indicate the cytogenetic and mutation analysis during the study period. All patients were taking imatinib during the period shown, unless switched to dasatinib when noted.